A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

NCT07121413 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis(IPF)

Interventions

DRUG: SV001
DRUG: Placebo

Sponsor

Shanghai Synvida Biotechnology Co.,Ltd.